Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Sekisui Diagnostics’ OSOM rapid immunochemical fecal occult blood test detects hemoglobin in stool samples as an aid in the early detection of colorectal cancer. The OSOM test provides sample stability: a unique “dry-sample” collection card; value: two patient sample collections on one collection card allow compliance with screening guidelines, using only one test cassette; and a comprehensive physician and patient support Web site.
Working in conjunction with Arotec Diagnostics, The Binding Site offers myeloperoxidase (pANCA) antigen. Antibodies to myeloperoxidase have been observed in systemic vasculitis, glomerulonephritis, rheumatoid arthritis, and inflammatory bowel disease. Elevated plasma levels also have been reported in acute coronary syndromes and with some malignancies.
American Esoteric Laboratories (AEL) has expanded its test offerings for women, with the addition of its Trichomonas amplified probe test, and improved its high-risk HPV testing capabilities.
BioTheranostics’ Prostate Cancer Index is a strong predictor of prostate cancer recurrence and may improve upon the current standard of care for assessing risk of recurrence and metastasis in patients with prostate cancer, according to a study published online in the Proceedings of the National Academy of Sciences (doi:10.1073/pnas.1215870110. Epub March 26, 2013).
BD Diagnostics in April announced an international distributor agreement with Bruker Daltonics to sell and provide frontline technical support for the co-labeled BD Bruker MALDI Biotyper system. The system, combined with automated antimicrobial susceptibility testing on the BD Phoenix microbiology system and BD EpiCenter microbiology data management system, will facilitate a fully integrated, optimized approach for laboratory workflow.
Streck’s CD-Chex CD117 is a flow cytometry control for CD117. The control eliminates the need for laboratories to hold and validate patient samples to use as a control for CD117, saving time and money. CD-Chex CD117 is designed to represent abnormal peripheral blood leukocytes similar to a hematolymphoid neoplastic patient sample. The product has surface CD117 that is detectable with fluorescent monoclonal antibodies by flow cytometry. The CD117 positive abnormal leukocytes are distinguishable from normal leukocytes on the basis of light-scatter properties, a low level of CD45 expression, and heterogeneous CD117 expression.
BioFire Diagnostics has submitted to the FDA its FilmArray blood culture identification (BCID) panel. The panel received the CE Mark earlier this month. The submission comes after completion of clinical trials for the FilmArray BCID panel, which provides automatic results for common infectious causes of sepsis. BioFire anticipates commercial release of the panel this summer, pending FDA clearance.
Randox Toxicology has developed an ELISA that targets UR-144, XLR-11, and additional synthetic cannabinoid compounds, which are commonly found in new “Spice” and “K2” blends. Together with the company’s JWH/AM2201 synthetic cannabinoids ELISA, the UR-144/XLR-11 ELISA provides a comprehensive solution for the rapid detection of more than 55 current synthetic cannabinoids in urine, blood, and oral fluid.
The Center for Phlebotomy Education is holding the Phlebotomy Supervisor’s Boot Camp July 10-12 and Nov. 6-8 in Louisville, Ky. Educators, phlebotomy supervisors, and lab managers who attend will acquire new skills and strategies for staff development, technical instruction, mentoring, and coaching professionalism. The presenters are Catherine Ernst, RN, PBT(ASCP), Lisa Steinam, PBT(ASCP), and Dennis Ernst, MT(ASCP).
With a recent software upgrade (V2.5/2.3.0.0) and new adapter for its Clinitek Status Connect urine chemistry system, Siemens Healthcare Diagnostics now offers hospitals and clinicians seamless wireless connectivity and improved bar-coding capabilities for point-of-care urinalysis testing. These enhancements enable greater flexibility, risk management, and speed.
